Vaginal misoprostol as medical treatment for first trimester spontaneous miscarriage.
BACKGROUND
Misoprostol is effective for cervical priming prior to suction evacuation in first trimester pregnancy termination. This is the first randomized study to compare vaginal misoprostol versus expectant treatment in women presenting with spontaneous miscarriage.


METHODS
Sixty women presenting with spontaneous miscarriage were recruited to the study at the Queen Mary Hospital between 1998 and 1999. They were randomized to group 1: misoprostol; and group 2: expectant management. Women in the misoprostol group received vaginal misoprostol 400 microg on days 1, 3 and 5. The expectant group was followed up according to the same schedule. Suction evacuation was performed if there was excessive bleeding or abdominal pain; or if a gestational sac was detected by transvaginal scan on day 15.


RESULTS
Fifty-nine women completed the trial. Those who did not require suction evacuation up to the time of return of normal menstruation were considered to be successful. The incidence of side-effects was comparable between the two groups. Three women in the expectant group and one in the misoprostol group underwent emergency suction evacuation because of excessive bleeding. The mean duration of vaginal bleeding was similar for both groups (14.6 days in the misoprostol group versus 15.0 days in the expectant group). The successful rate in the misoprostol group was significantly higher than that of the expectant group (83.3 versus 48.3%, P < 0.05).


CONCLUSIONS
We recommend repeated vaginal misoprostol 400 microg given on days 1, 3 and 5 as a treatment option for women with first trimester spontaneous miscarriage.
Ngai
S W
SW
Department of Obstetrics and Gynecology, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China. cora@hkucc.hku.hk
Chan
Y M
YM
Tang
O S
OS
Ho
P C
PC
D000022:Abortion, Spontaneous / Q000188:drug therapy*; D000282:Administration, Intravaginal; D000328:Adult; D004638:Emergency Treatment; D005260:Female; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D010120:Oxytocics / Q000008:administration & dosage* / Q000627:therapeutic use; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D016896:Treatment Outcome; D014592:Uterine Hemorrhage / Q000601:surgery; D014620:Vacuum Extraction, Obstetrical
D010120:Oxytocics; D016595:Misoprostol